MARGetuximab Or Trastuzumab (MARGOT)

Clinical trial NCT04425018 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT04425018
Sponsor: Dana-Farber Cancer Institute
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Breast Cancer Stage II Breast Cancer Stage III Breast Cancer HER2-positive Breast Cancer

Start date: 2020-07-13
Primary completion: 2024-10-24
Enrollment: 174

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.